Related Experiment Video

Updated: Jun 10, 2025

A Soluble Tetrazolium-Based Reduction Assay to Evaluate the Effect of Antibodies on Candida tropicalis Biofilms
06:50

A Soluble Tetrazolium-Based Reduction Assay to Evaluate the Effect of Antibodies on Candida tropicalis Biofilms

Published on: September 16, 2022

3.1K

The effect of clozapine on immune-related biomarkers in schizophrenia patients

Lu Shao1, Yu Li1, ZhiYao Yuan1

  • 1School of Rehabilitation Medicine, Sanquan College of Xinxiang Medical University, XinXiang, HeNan, China.

Brain Research Bulletin
|October 18, 2024
PubMed

Insights

This review explores how clozapine affects immune markers in schizophrenia patients. Understanding these changes could help predict treatment response and improve outcomes for therapy-resistant schizophrenia (TRS).

Area of Science:

  • Psychiatry
  • Immunology
  • Pharmacology

Background:

  • Schizophrenia affects 1% of the population, with 30% showing resistance to standard treatments.
  • Clozapine is the primary treatment for therapy-resistant schizophrenia (TRS), but it has limitations and potential adverse effects.
  • Immune system alterations and changes in cytokine profiles have been observed in schizophrenia patients treated with clozapine.

Purpose of the Study:

  • To conduct a comprehensive review of the impact of clozapine on immune-related biomarkers in schizophrenia patients.
  • To explore the relationship between peripheral immune markers and clozapine response.
  • To identify potential biomarkers for predicting clozapine efficacy in TRS.

Main Methods:

  • Systematic literature search for studies investigating clozapine's effects on immune biomarkers.
  • Analysis of immune markers, including cytokines and cell populations, in schizophrenia patients.
  • Review of studies correlating immune marker changes with clozapine treatment response.

Main Results:

  • Clozapine treatment is associated with significant alterations in various immune system parameters.
  • Specific immune markers show differential changes that may correlate with treatment response or adverse events.
  • Evidence suggests a link between the immune system modulation by clozapine and its therapeutic effects in TRS.

Conclusions:

  • Immune-related biomarkers hold potential for predicting clozapine response in schizophrenia.
  • Further research into these biomarkers could lead to personalized treatment strategies for TRS.
  • Identifying predictive biomarkers may reduce treatment delays and improve patient outcomes.
Keywords:
BiomarkerClozapineImmune systemSchizophrenia

More Related Videos

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays06:03

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays

Published on: September 20, 2024

1.2K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.2K

Related Concept Videos

Biological Causes of Schizophrenia01:29

Biological Causes of Schizophrenia

Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
46
Negative and Cognitive Symptoms of Schizophrenia01:30

Negative and Cognitive Symptoms of Schizophrenia

Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
44
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
143
Schizophrenia01:17

Schizophrenia

Schizophrenia, a term introduced by Swiss psychiatrist Eugen Bleuler in 1911, describes a severe psychological disorder marked by profound disruptions in attention, thought processes, language, emotion, and interpersonal relationships. The core feature of schizophrenia is psychosis — a state characterized by a fundamental detachment from reality. This disconnection manifests through distorted logic, impaired perception, and atypical behavior, severely affecting the lives of those...
70
Psychological and Sociocultural Causes of Schizophrenia01:29

Psychological and Sociocultural Causes of Schizophrenia

Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...
80